...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Another IPO that shocks!

,,,yes,,3 years or maybe more,,,insiders and kamanegment will have to fill their pockets first by dragging the research out,,,,the differene I see between a US exchange and our Canadian exchanges is that the US actually builds in the speculation price well prior to success. Here in Canada the interest in biotech is so completely off radar it is wonder why any company would actually want to list here. It is a lesson learned the hard way for retail investors! jmo

Share
New Message
Please login to post a reply